Background: Biologic therapies have revolutionised the treatment of immune-mediated diseases including inflammatory bowel disease [IBD] and rheumatological disorders. However, biologic treatments are associated with an increased risk of reactivation of latent tuberculosis. Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking. Methods: Consecutive patients eligible for biologic therapies were screened for LTBI and prospectively followed up for 3 years. Incidence and risk factors of latent tuberculosis tests conversion (interferon gamma release assays [IGRA] received isoniazid monotherapy for 9 months. Age, sex, smoking status, alcohol use, travel history, disease type, and immunosuppressive therapy were not associated with LTBI test conversion. In subjects with IGRA conversion, serial IGRA levels normalised after completion of isoniazid except in one patient whose IGRA remained persistently elevated despite isoniazid and who subsequently developed active TB. Conclusions: Conversion of LTBI is common and occurred early during biologic therapy in an area with intermediate TB burden. Subjects with latent TB tests conversion and persistently high IGRA levels may have an increased risk of TB reactivation or development of active TB, and they require close observation or intensive workup for active TB.
Introduction
Biologic agents, including tumour necrosis factor [TNF] antagonist, are effective and are increasingly being used for the treatment of immunemediated inflammatory diseases [IMIDs] , including rheumatoid arthritis [RA] , inflammatory bowel disease [IBD] , ankylosing spondylitis, and psoriasis. [1] [2] [3] Exposure to Mycobacterium tuberculosis [Mtb] often results in the development of latent tuberculosis infection [LTBI] with a 5-10% lifetime risk of progressing to active tuberculosis [TB] in immunocompetent hosts. 4 However, reactivation of latent TB is more common in the setting of biologic therapies. [5] [6] [7] [8] The use of anti-TNF treatment in patients with Crohn's disease and rheumatoid disorders has been associated with an approximately 14-fold increase risk of TB reactivation compared with healthy controls. 9 The risk is further increased to over 40-fold if a combination of anti-TNF agent and immunomodulator is used. 8 More than 50% of cases were extrapulmonary disease and most cases occurred in endemic regions. 4 Hong Kong is a region of intermediate TB burden, and the reactivation of latent TB in patients treated with biologics is a major public health concern.
Current guidelines recommending TB screening 10, 11 and LTBI treatment before using biologics have had a substantial impact on reducing the incidence of TB. 12, 13 Preventive therapy with daily isoniazid offers 60% to 90% protection and combination therapies [daily isoniazid-rifampicin or weekly isoniazid-rifapentine] are effective alternatives. 14 Tuberculin skin testing [TST] and interferon gamma release assay [IGRA] are currently two accepted methods for screening Mtbexposed individuals for LTBI. False-positive results can occur as a result of boosting from repeated TST, previous bacillus CalmetteGu´erin [BCG] vaccination, or infection with non-tuberculous mycobacteria. 15 Since BCG vaccination was introduced in Hong Kong in 1952, more than 99% of newborn infants have received BCG vaccination at birth. 16 TST may also be falsely negative in immunocompromised patients, due to either the underlying diseases or the immunosuppressive therapy. [17] [18] [19] A false-negative TST may also occur during active IBD without immunosuppression. 20 Recently interferon gamma release assays [IGRAs] have been introduced to compensate for the drawbacks of TST in detecting LTBI. Studies have shown that IGRAs are superior to TSTs in identifying LTBI in immunosuppressed and BCG-vaccinated populations. 21, 22 However, work from our group 23 and a meta-analysis 24 have shown that immunosuppressive therapy may also negatively affect the results of IGRA. Although studies have shown that both IGRA conversion and reversion may occur during the course of immunosuppressive therapy, 25, 26 prospective studies assessing the value of monitoring IGRAs in patients with IMID on biologic therapy in countries with intermediate to high TB incidence are lacking. This is particularly important, as these countries are also experiencing a rising incidence of IBD accompanied by increased use of biologics in the past decade. 27 This study aimed to assess the frequency of LTBI test conversion and the subsequent risk of TB during long-term biological therapy in patients with IMIDs. Such data will inform us whether regular TB monitoring is required during biologic therapy in TB-endemic areas. This study can potentially have an impact on the current guidelines regarding monitoring of TB during biologic therapy. Clinical data of disease characteristics and concomitant medications were collected at baseline and at each follow-up. At baseline, history of BCG vaccination, previous personal, family, and occupational tuberculosis exposure, travel and immigration history, and smoking status were recorded. Travel history to a high-risk area during the study period was defined as any visit to high TB-burden countries according to the World Health Organization Global Tuberculosis Report 2016. A history of comorbidities including diabetes mellitus, liver cirrhosis, chronic obstructive pulmonary disease [COPD] , nad chronic kidney disease [CKD] , were recorded from the clinical consultation notes.
Materials and Methods

Data source and study design
Bfore commencement of biologic therapy, the TST and IGRA tests and a chest X-ray [CXR] were performed in all patients. Patients with a positive TST, IGRA or CXR indicative of latent tuberculosis were given prophylactic TB treatment based on the clinician's assessment and discretion before commencement of biologic therapy. We followed local guidelines by using isoniazid monotherapy for 9 months, 28 and the biologics were not started until completing 1 month of isoniazid prophylaxis. Subjects were followed up every 4 months. At each visit, a detailed interview including history of fever, weight loss, chills, cough, and exposure to TB were obtained. All subjects had a CXR every 6-8 months, repeat IGRA every 4months, and a TST every 12 months during biolog therapy for up to 3 years. Any individual with a positive TST, IGRA, or CXR indicative of latent tuberculosis were screened for active TB, and referred to an infectious disease physician for management as necessary.
This study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee. Informed consent was signed by all participants before participation in this study.
Definitions
TB screening test
IGRA was performed using the QFT-G assay [Cellestis, Melbourne, Australia] by a trained technician blinded to the results of the diagnosis and blood tests, in accordance with the manufacturer's instructions. In brief, 1 mL aliquot of heparinised blood from each subject was incubated within 12 h of blood collection with stimulation antigens [ESAT-6, CFP-10, TB-7.7, and mitogen] and nil control for 16 to 24 h at 37°C. Plasma was then harvested for interferon gamma measurement using enzyme-linked immunoassay. The result was calculated using the QFT-G analysis software. The result was considered positive if ESAT/CFP-10 minus nil control were ≥0.35 IU/mL and ≥25% of nil, or negative if mitogen minus nil was ≥0.5 IU/mL, or indeterminate if mitogen minus nil was <0.5 IU/mL.
TST was performed by injecting 0.1 mL [2 units] of tuberculin purified protein derivative RT23 [Statens Serum Institut, Copenhagen, Denmark] intradermally over the forearm. The induration was evaluated 48 to 72 h after the injection, by a trained physician. TST was considered positive if the diameter of induration was ≥5 mm in size.
Postero-anterior CXRs were interpreted by an experienced radiologist [EH] . Findings were divided into three categories: normal, positive with suspicion of latent TB, or positive with suspicion of consolidation, malignancy, or other findings. Findings on CXR indicative of latent TB included apical or basal pleural thickening, fibrous scarring, calcified granuloma, or lymph nodes.
Latent TB infection and active TB
LTBI was defined as having at least one screening test [TST, IGRA, or CXR] positive, whereas active TB was defined as having active symptoms consistent with TB with positive microbiological evidence of TB (positive acid-fast bacillus smear, TB culture, or polymerase chain reaction [PCR]).
IGRA conversion was defined by a reproducibly positive result under biological therapy after a negative baseline test. TST conversion was defined by the negative baseline TST becoming positive [≥5 mm of induration] under biological therapy. 29 CXR conversion was defined by new X-ray features indicating active TB after a normal CXR at baseline. Reversion was defined as a negative test result after a positive result in previous tests.
Biologic and immunosuppressive therapies
The dosage, frequency, and route of administration of biologic therapies were given according to the standard prescription information of the respective drugs, and adjustments were made accordingly based on patients' clinical conditions and clinicians' discretion. Immunosuppressive medication was defined as ≥15 mg/day of prednisone or equivalent for 1 month or longer, 29, 30 or any dose of azathioprine, 6-mercaptopurine, or methotrexate and leflunomide. Biological therapies included infliximab, adalimumab, certolizumab, golimumab, etanercept, ustekinumab and tocilizumab. 
Statistical analysis
Results
Patient characteristics
. Among these patients, four were initially on infliximab and subsequently switched to adalimumab due to a loss of response, and two switched from etanercept to golimumab.
At baseline, 18 patients [16.7%] tested positive for LTBI [three IGRA-positive, nine TST-positive, one CXR-positive, and five both IGRA-and TST-positive]. These patients positive for LTBI at baseline comprised one UC and two PA patients with IGRA positivity alone; three CD, three RA, one AS, and two PA patients with TST positivity alone; one CD patient with CXR positivity alone; and one RA, one psoriasis and three PA patients with both IGRA and TST positivity [ Table 2 ].
A total of 14 out of 18 patients positive for latent TB infection were given isoniazid monotherapy before commencing biologic therapy. Three of the psoriasis patients [two IGRA-positive and one both IGRA-and TST-positive] were diagnosed with latent TB previously [between 2008 and 2010 and completed isoniazid prophylaxis] and one CD [with CXR suggestive of LTBI which showed right upper and middle zone fibrosis] had a history of mycobacterium avian complex disease in 2006 and had completed a full course of anti-mycobacterial treatment. All these four patients were not given any more isoniazid prophylaxis before initiation of biologic therapy.
Conversion of LTBI tests
Patients were followed up for a median of 16 months (interquartile range [IQR]: 6-24). Among patients with a negative baseline test for LTBI [n = 90; 18 patients with IBD, 12 with rheumatic diseases patients with rheumatic diseases], 17 [18.9%] had a conversion with one or more of the TB tests from negative to positive [ Table 3 ]. Fourteen of these patients with conversion of LTBI tests received isoniazid prophylaxis during their course of biologic treatment which was not interrupted. One patient with CD had conversion of TST and IGRA, and later developed active TB despite completion of isoniazid treatment. One CD patient had only IGRA conversion 5 months after stopping the biologic treatment [biologic treatment was stopped earlier, as patient achieved mucosal healing and was in deep remission]. Another two CD patients with TST conversion were not given isoniazid, based on the discretion of the treating doctors.
Factors associated with TB test conversion
Univariate analysis was performed to examine factors associated with LTBI conversion. None of the factors, including age, sex, smoking status, alcohol, travel history to high TB-burden countries, type of disease, type of biologic treatments [anti-TNF or non anti-TNF], or changes of immunosuppressive therapies after initiation of biologic treatment, was significantly associated with LTBI conversion in univariate analysis [ Table 4 ]. There were nor significant association factors in terms of IGRA conversion [ Table 5 ].
Patient developing active tuberculosis
Out of 108 patients, one CD patient [male, aged 27] developed active TB at 20 months after commencement of infliximab. Initial screening for TB was negative. This patient had IGRA seroconversion 4 months after initiation of infliximab. He received isoniazid prophylaxis for 9 months. Seven months after completion of LTBI treatment, he presented with fever and cough with whitish sputum. His chest radiography showed right upper zone consolidation. Bronchoscopy was performed, and bronchoalveolar lavage was positive for acid-fast bacillus [ Figure 1 ]. None of these patients developed active TB during the study period.
For those with IGRA conversion [n = 6; three with IGRA alone, three with both IGRA and TST], their IGRA at conversion was in the range of 0.57-20.57. Most of them [4/6, 66.7%] had conversion during the first 6 months of initiation of biologic treatment. Among those who were treated with isoniazid [four CD and one psoriasis; one CD was not treated, as mentioned earlier], the IGRA was negative at the end of isoniazid treatment [ Figure 2 ] except one [IGRA of 20.57 during conversion, remaining elevated at 7.58 after 3 months' completion of isoniazid prophylaxis] who subsequently developed active TB.
Pattern of changes of tuberculin tests for baseline LTBI=positive patients and those with LTBI tests conversion
There were 14 patients with baseline positive tuberculin tests. Twelve of these received isoniazid and the other two had completed isoniazid prophylaxis before recruitment into the study. After completion of isoniazid, seven had persistently positive tuberculin tests at 1 year as per protocol. Three other patients had subsequent negative tuberculin tests. For those not treated with isoniazid, one had persistently positive tests and one had negative tuberculin tests upon repeated testing.
Overall, the reversion rate of those with baseline positive tuberculin tests after completion of isoniazid was 30% [3/10 excluding two subjects who had not yet repeated their tuberculin tests]. CD, Crohn's disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease unclassified; TST, tuberculin skin test; IGRA, interferon gamma release assays; CXR, chest X-ray. On the other hand, nine patients had conversion of their tuberculin tests, all of whom received isoniazid prophylaxis. For those with conversion of tuberculin tests upon completion of LTBI treatment, three had reversion, two remained positive, and another four had yet to repeat their tuberculin tests.
Discussion
In this prospective study comprising mainly IBD patients followed up for a median of 2 years, we found that latent TB tests conversion is common in a region of intermediate to high TB incidence. During the follow-up, none of the subjects who had positive LTBI tests at baseline developed active TB during or after treatment with isoniazid prophylaxis. Furthermore, in those who had LTBI test conversion after initiation of biologic therapy, one patient with IBD developed active TB despite isoniazid prophylaxis. Overall, 16.7% patients had baseline positive latent TB before biologic treatment [most of whom received isoniazid] and 18.9% of the remaining patients had conversion of any one of the latent TB tests during biologic therapy. Isoniazid monotherapy showed effective protection in 96% [27/28] of subjects against the development of active TB in our IMID cohort with LTBI. Our findings were slightly higher compared with an earlier study reporting an incidence of active TB of 1.65% despite LTBI screening and treatment, and the majority of cases appeared within the first 4 months after starting therapy.
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All six patients who had IGRA conversion were on other immunosuppressive medications, which may explain the possibility of false-negative results at baseline. We repeated TST on an annual basis rather than at shorter intervals, in order to reduce the 'boosting phenomenon' due to repeated TST. Boosting is maximal if the interval between the first and second test is between 1 and 5 weeks 32, 33 and is much less frequent if the interval is only 48 h 34 or more than 60 days. 32 Hence in this group of patients, even though the IGRAs were negative, we believe the TST conversion was genuinely representative of latent TB due to likely re-exposure in this country after initiation of biologic therapy.
The lower prevalence of LTBI among IBD patients could be due to false-negative results secondary to steroid use which is common in IBD patients before escalation to immunomodulators or biologics. In contrast, steroids are less commonly used in the rheumatological cohorts comprising mostly patients with psoriasis. The exact cause for the higher conversion on biologics in CD [most of whom were on infliximab] compared with UC or rheumatology patients is unclear, but may relate to disease and patient factors whereby CD patients require more frequent visits or hospitalisation and are more likely to be exposed.
The value of monitoring IGRA during treatment of both active and latent TB has been controversial. However, we believe that IGRA in addition to CXR has an important role in detection of TB, since more than 50% of reactivation occurred at extrapulmonary sites. A recent meta-analysis showed that IGRA quantitatively dropped with treatment but with substantial variation among studies, and hence it may not be useful in clinical practice. 35 Our cohort showed that IGRA levels dropped in those who had conversion but not in those with baseline IGRA positivity after treatment with isoniazid. Besides, all three psoriasis patients with baseline IGRA positivity, yet not treated with isoniazid [background history of past latent TB and completed treatment many years ago], demonstrated great variation in changes of IGRA level during biologic treatment.
One recent study had shown that conversion at interferon gamma values higher than 4.00 IU/mL was linked to a more than 40 times higher risk of developing tuberculous disease in the following 6 to 24 months (incidence rate ratio [IRR] 36 Our data were consistent with this observation, even though the number of IGRA conversions was small. Five out of the six IGRA converters had levels below 4 IU/ml, and none of them developed active TB after isoniazid prophylaxis. Papay et al. showed that in patients with negative LTBI at baseline, IGRA conversion during biologic therapy occurred but was usually transient and results generally turned negative upon repeated testing. Although no was isoniazid given, none of the subjects developed active TB after a median of 39 months' follow-up. 26 However, in our cohort, the decision to initiate isoniazid prophylaxis was based on a single IGRA conversion result rather than repeated samples. In contrast, the one patient who had IGRA levels persistently higher than 4 IU/ml developed active TB despite completion of isoniazid prophylaxis.
The most reassuring observation from this study is that none of the patients with negative IGRA tests during biologic treatment developed TB during follow-up. These data suggest that false-negative results during therapy are less likely. In addition, our study showed that serial IGRAs have a meaningful role in monitoring subjects who had LTBI test conversion during biologic therapy. Subjects with persistently high IGRAs of more than 4 IU/ml upon completion of isoniazid prophylaxis may be at an increased risk of development of active TB, and require closer observation or intensive workup for active TB. In contrast, in subjects with a positive baseline latent TB tests, the role of serial IGRA monitoring during biologic treatment remains to be defined by longer and larger prospective studies. The main limitation of our study is a modest sample size and a relatively short period of follow-up for patients with baseline IGRA positive results, who may develop active TB later. It is also likely that monitoring with yearly CXR and IGRA will be sufficient for latent TB monitoring.
In clinical practice, we often face the conundrum of indeterminate IGRA results, especially in patients on immunosuppressive treatments. Studies have shown that indeterminate results are associated with steroid and immunosuppressants use. 37, 38 Hence we recommend latent TB testing before initiation of immunosuppressants in patients at high risk in anticipation of escalation of treatment. 23 In conclusion, latent TB tests conversion is common and occurs early during biologic treatment. Isoniazid monotherapy prophylaxis is effective in prevention of active TB. Serial IGRAs may have a role in monitoring those with latent TB tests conversion.
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